AnaptysBio Announces Second Quarter 2019 Financial Results and?Provides Pipeline Updates

August 8, 2019 sandiegobiotech News Comments Off on AnaptysBio Announces Second Quarter 2019 Financial Results and?Provides Pipeline Updates
AnaptysBio Announces Second Quarter 2019 Financial Results and?Provides Pipeline Updates
/

SAN DIEGO, Aug. 08, 2019 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today reported operating results for the second quarter ended June 30, 2019 and provided pipeline updates.

Related Articles

No Picture
News

AnaptysBio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

September 10, 2021 sandiegobiotech News Comments Off on AnaptysBio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present an overview of AnaptysBio… Click here to view original post… […]

No Picture
News

AnaptysBio Announces Agreement to Monetize Portion of JEMPERLI Royalties for $250 Million with Sagard

October 25, 2021 sandiegobiotech News Comments Off on AnaptysBio Announces Agreement to Monetize Portion of JEMPERLI Royalties for $250 Million with Sagard

SAN DIEGO, Oct. 25, 2021 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced the signing of an agreement with Sagard Healthcare Royalty Partners to monetize a portion of… Click here to view original post… […]

No Picture
News

AnaptysBio Reports Etokimab ATLAS Phase 2b Clinical Trial in Moderate-to-Severe Atopic Dermatitis Fails to Meet Primary Endpoint

November 8, 2019 sandiegobiotech News Comments Off on AnaptysBio Reports Etokimab ATLAS Phase 2b Clinical Trial in Moderate-to-Severe Atopic Dermatitis Fails to Meet Primary Endpoint

SAN DIEGO, Nov. 08, 2019 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced topline data fr… […]